Antimony 400micrograms/100g ointment
Antimony has been used in trials studying the treatment of Cutaneous Leishmaniasis.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(13)
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis (TA1155)
Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) (TA941)
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)
Hepatitis B (chronic): diagnosis and management (CG165)
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)
Thyroid cancer: assessment and management (NG230)
Coeliac disease: recognition, assessment and management (NG20)
Food allergy in under 19s: assessment and diagnosis (CG116)
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)
The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA658)
Irritable bowel syndrome in adults: diagnosis and management (CG61)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 14 · 1925–2022
Showing the 50 most relevant studies, sorted by most relevant.
Hongwei Lei, Jianjun Chen, Zuojun Tan, et al.
Solar RRL, 2019
Kai Zeng, Ding‐Jiang Xue, Jiang Tang
Semiconductor Science and Technology, 2016
Xiaomin Wang, Rongfeng Tang, Chunyan Wu, et al.
Journal of Energy Chemistry, 2017
Pengfei Guo, A. Sarangan, I. Agha
Applied Sciences, 2019
Jingxin Li, Qian Wang, Ronald S. Oremland, et al.
Applied and Environmental Microbiology, 2016
- Metabolic Networks and Pathways
- Antimony
- Bacteria
Anton Saerens, Manosij Ghosh, J. Verdonck, et al.
International Journal of Environmental Research and Public Health, 2019
David Dupont, Sander Arnout, Peter Tom Jones, et al.
Journal of Sustainable Metallurgy, 2016
Padala Abdul Nishad, Anupkumar Bhaskarapillai
Chemosphere, 2021
- Environmental Pollutants
- Soil Pollutants
- Water Pollutants, Chemical
Montserrat Filella, N. Belzile, Yuwei Chen
Earth-Science Reviews, 2002
Montserrat Filella, Nelson Belzile, Marie‐Claire Lett
Earth-Science Reviews, 2006
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Investigational
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Antimony
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Molecular structure
Linked open data from Wikidata (Q1099), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. Molecular structure images from Wikimedia Commons.